Transforming the Traditional Drug Development Model

Abstract

For more than a decade, the pharmaceutical industry has been facing mounting public, government, and internal pressure to contain development costs, lower drug prices, and ramp up pipelines faster. At the same time, the cost, complexity and globalization of drug development continues to escalate. These challenges plus financial, political and scientific developments are driving a transformation in the traditional biopharmaceutical business model.